Applies to the following strength(s): 10 mg ; 5 mg ; immediate release ; 2 mg/mL ; extended release ; 7 mg ; 14 mg ; 21 mg ; 28 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Alzheimer's Disease
Week 1: 5 mg orally once a day.
Week 2: 10 mg orally/day (Administer 5 mg twice a day.)
Week 3: 15 mg orally/day (Administer 5 mg and 10 mg as separate doses.)
Week 4/Maintenance Dose: 20 mg orally/day (Administer 10 mg twice a day.)
-Initial Dose: 7 mg orally once a day.
-Maintenance and Maximum Dose: 28 mg orally once a day; increase the initial dose in 7 mg increments to the recommended maintenance dose.
Comments: The minimum recommended interval between dose increases is one week; only increase dosage if the previous dose has been well tolerated.
Use: Treatment of moderate to severe dementia of the Alzheimer's type.
Renal Dose Adjustments
-Mild and Moderate Renal Impairment (CrCl 30 to 80 mL/min): No adjustment recommended.
-Severe Renal Impairment (CrCl 5 to 29 mL/min): Immediate-Release: 5 mg orally twice a day; Extended-Release (Maintenance and Maximum Dose): 14 mg orally once a day.
Liver Dose Adjustments
-Mild and Moderate Hepatic Impairment (Child-Pugh A and B): No adjustment recommended.
-Severe Hepatic Impairment (Child-Pugh C): Immediate-Release: Use with caution; Extended-Release: Data not available.
SWITCHING FROM IMMEDIATE-RELEASE (IR) TO EXTENDED RELEASE (XR):
-Patient on Regimen of 10 Mg IR Twice a Day: Switch to 28 mg XR once a day on the day following the last dose of the IR drug.
-Patients with Severe Renal Impairment (CrCl 5 to 29 mL/min): Switch to 14 mg XR once a day on the day following the last dose of the IR drug.
-Comments: There is no study data addressing the comparative efficacy of the 10 mg IR twice a day and 28 mg XR once a day regimens.
FAILING TO TAKE THE DRUG (IR or XR) FOR SEVERAL DAYS: Consider resuming treatment at a lower dose and re-titrate according to the standard titration scheme.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available.
-Administer this drug with or without food.
-In the event of a missed dose, advise patients to take the next dose as scheduled and not to double up on that dose.
-EXTENDED-RELEASE CAPSULES: May be opened and its contents sprinkled on applesauce; instruct patients to consume the entire contents of each capsule and not to divide the dose.
-EXTENDED-RELEASE CAPSULES: Except when opened and sprinkled on applesauce, advise patients to swallow the capsules whole and not to divide, chew, or crush them.
-ORAL SOLUTION: Consult the manufacturer product information for instructions on use of the dosing device that comes with this drug formulation.
-ORAL SOLUTION: Do not mix with any other liquid; consult the manufacturer product information for preparation/handling instructions.
-Overdosage: No specific antidote is available; use standard clinical procedures such as urine acidification, carbo medicinalis (interruption of potential entero-hepatic recirculation), gastric lavage, and forced diuresis as appropriate.
-ORAL SOLUTION: If using the bottle with the mounted pump, keep and transport the bottle in a vertical position.
-Reassess the clinical benefit, tolerance, and dosing of this drug on a regular basis, preferably within 3 months after treatment initiation and according to current clinical guidelines thereafter.
-Avoid potentially dangerous activities such as driving and operating machinery until you know how this drug affects you.
More about memantine
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 28 Reviews – Add your own review/rating
- Drug class: miscellaneous central nervous system agents
- Memantine extended-release capsules
- Memantine solution
- Memantine tablets
- Memantine (Advanced Reading)